News round-up for by DDW Digital Content Editor Diana Spencer.
The news headlines this week reflect the level of interest in cell & gene therapies (CGT) in the sector, particularly CAR-T, but also the importance of research collaborations to bring these therapies to patients. Traditionally successful in treating blood cancers, it is positive to see companies pursuing CAR-T as an option for solid tumours, a potential new market for these treatments.
The top stories:
BlueRock and bit.bio sign Treg therapies discovery deal
Bayer subsidiary BlueRock Therapeutics and bit.bio have announced a collaboration to discover and manufacture regulatory T cell (Treg) based therapies.
Research partners advance AAV gene therapy for heart disease
Evox Therapeutics has agreed a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) in New York, NY, US.
Astellas invests in CAR-T cell therapy for solid tumours
Astellas Pharma will invest $50 million into Poseida Therapeutics to secure the rights to the company’s cancer CAR-T cell therapy for solid tumours, which is currently in Phase I trials.
Biologic CAR-T cell engager approved for UK clinical trial
The UK MHRA has granted Aleta Biotherapeutics a clinical trial authorisation to evaluate biologic ALETA-001 in a Phase I/II clinical trial in patients with B-cell malignancies who are relapsed/refractory to CD19 CAR-T cell therapy.
Collaborators agree deal to develop CAR-T therapy for solid tumours
GenScript Biotech and T-MAXIMUM Biotech have formed a strategic collaboration to develop T-MAXIMUM’s CAR-T cell therapy using GenScript’s CRISPR nucleic acid reagents.
